[{"id":"8ce17564-4a45-43a3-9a95-423caa8fe9c6","acronym":"KEYNOTE-E45","url":"https://clinicaltrials.gov/study/NCT05394103","created_at":"2022-05-27T12:55:37.575Z","updated_at":"2025-02-25T16:17:45.159Z","phase":"Phase 1/2","brief_title":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","source_id_and_acronym":"NCT05394103 - KEYNOTE-E45","lead_sponsor":"Qurient Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mocaciclib (Q901)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 08/30/2022","start_date":" 08/30/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2024-03-12"}]